ATE512133T1 - 1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs - Google Patents
1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebsInfo
- Publication number
- ATE512133T1 ATE512133T1 AT06709213T AT06709213T ATE512133T1 AT E512133 T1 ATE512133 T1 AT E512133T1 AT 06709213 T AT06709213 T AT 06709213T AT 06709213 T AT06709213 T AT 06709213T AT E512133 T1 ATE512133 T1 AT E512133T1
- Authority
- AT
- Austria
- Prior art keywords
- carbonic acid
- acid amides
- fak
- kdr
- pyrrole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0501092A FR2881426B1 (fr) | 2005-02-03 | 2005-02-03 | Pyrolles et imidazoles substitues, compositions les contenant, procede de frabrication et utilisation |
| PCT/FR2006/000220 WO2006082309A1 (fr) | 2005-02-03 | 2006-02-01 | l-H-PYROLE-2-CARBOXAMIDES ET IMIDAZOLE-5-CARBOXAMIDES ET LEUR UTILISATION EN TANT MODULATEURS DES KINASES FAK, KDR ET TIE2 POUR TRAITER LE CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE512133T1 true ATE512133T1 (de) | 2011-06-15 |
Family
ID=34954950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06709213T ATE512133T1 (de) | 2005-02-03 | 2006-02-01 | 1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7560571B2 (de) |
| EP (1) | EP1856043B1 (de) |
| JP (1) | JP2008528661A (de) |
| KR (1) | KR20070103420A (de) |
| CN (1) | CN101133023A (de) |
| AR (1) | AR053540A1 (de) |
| AT (1) | ATE512133T1 (de) |
| AU (1) | AU2006210343A1 (de) |
| BR (1) | BRPI0606761A2 (de) |
| CA (1) | CA2595987A1 (de) |
| EA (1) | EA012267B1 (de) |
| FR (1) | FR2881426B1 (de) |
| IL (1) | IL184710A0 (de) |
| MA (1) | MA29264B1 (de) |
| MX (1) | MX2007009442A (de) |
| NO (1) | NO20074414L (de) |
| TW (1) | TW200640857A (de) |
| UY (1) | UY29361A1 (de) |
| WO (1) | WO2006082309A1 (de) |
| ZA (1) | ZA200706338B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2881742B1 (fr) | 2005-02-10 | 2007-09-07 | Aventis Pharma Sa | Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation |
| CA2648923A1 (en) * | 2006-04-11 | 2007-10-18 | Vertex Pharmaceuticals Incorporated | Thiazoles, imidazoles, and pyrazoles useful as inhibitors of protein kinases |
| AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| US8642628B2 (en) * | 2008-08-15 | 2014-02-04 | N30 Pharmaceuticals, Inc. | Pyrrole inhibitors of S-nitrosoglutathione reductase |
| DK2315591T3 (en) | 2008-08-15 | 2016-06-06 | Nivalis Therapeutics Inc | NOVEL PYRROLE INHIBITORS OF S-nitrosoglutathione-reductase as therapeutic agents |
| EP2318007B1 (de) | 2008-08-15 | 2013-01-23 | N30 Pharmaceuticals, Inc. | Neuartige pyrrolhemmer der s-nitrosoglutathion-reduktase als therapeutische mittel |
| CN102775354A (zh) * | 2011-05-10 | 2012-11-14 | 无锡立诺康医药科技有限公司 | 一种合成4-芳基-5-羧酸咪唑及其酯的工艺方法 |
| AU2013299557B2 (en) | 2012-08-10 | 2017-06-22 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Bruton's tyrosine kinase (BTK) inhibitors |
| EP3099674B1 (de) | 2014-01-29 | 2018-10-24 | Boehringer Ingelheim International Gmbh | Pyrazolverbindungen als btk-hemmer |
| CA3005268C (en) | 2015-12-16 | 2024-04-30 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as btk inhibitors |
| WO2017123695A1 (en) | 2016-01-13 | 2017-07-20 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020173507A1 (en) * | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| GB0107901D0 (en) | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
| JP2006515828A (ja) * | 2001-09-27 | 2006-06-08 | スミスクライン・ビーチャム・コーポレイション | 化学化合物 |
| US20040138269A1 (en) * | 2002-10-11 | 2004-07-15 | Sugen, Inc. | Substituted pyrroles as kinase inhibitors |
| MXPA05011702A (es) * | 2003-04-30 | 2006-01-23 | Pfizer Prod Inc | Agentes antidiabeticos. |
| DE10354060A1 (de) | 2003-11-19 | 2005-06-02 | Merck Patent Gmbh | Pyrrolderivate |
| US7183285B2 (en) | 2004-04-29 | 2007-02-27 | Pharmix Corp. | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase |
| FR2881742B1 (fr) | 2005-02-10 | 2007-09-07 | Aventis Pharma Sa | Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation |
-
2005
- 2005-02-03 FR FR0501092A patent/FR2881426B1/fr not_active Expired - Fee Related
-
2006
- 2006-01-26 TW TW095102965A patent/TW200640857A/zh unknown
- 2006-02-01 AR ARP060100362A patent/AR053540A1/es unknown
- 2006-02-01 WO PCT/FR2006/000220 patent/WO2006082309A1/fr active Application Filing
- 2006-02-01 BR BRPI0606761-1A patent/BRPI0606761A2/pt not_active IP Right Cessation
- 2006-02-01 AT AT06709213T patent/ATE512133T1/de not_active IP Right Cessation
- 2006-02-01 CA CA002595987A patent/CA2595987A1/fr not_active Abandoned
- 2006-02-01 EP EP06709213A patent/EP1856043B1/de active Active
- 2006-02-01 MX MX2007009442A patent/MX2007009442A/es not_active Application Discontinuation
- 2006-02-01 ZA ZA200706338A patent/ZA200706338B/xx unknown
- 2006-02-01 EA EA200701648A patent/EA012267B1/ru not_active IP Right Cessation
- 2006-02-01 AU AU2006210343A patent/AU2006210343A1/en not_active Withdrawn
- 2006-02-01 CN CNA2006800069922A patent/CN101133023A/zh active Pending
- 2006-02-01 JP JP2007553647A patent/JP2008528661A/ja active Pending
- 2006-02-01 KR KR1020077017902A patent/KR20070103420A/ko not_active Application Discontinuation
- 2006-02-03 UY UY29361A patent/UY29361A1/es unknown
-
2007
- 2007-07-18 IL IL184710A patent/IL184710A0/en unknown
- 2007-08-01 US US11/832,206 patent/US7560571B2/en not_active Expired - Fee Related
- 2007-08-23 MA MA30160A patent/MA29264B1/fr unknown
- 2007-08-29 NO NO20074414A patent/NO20074414L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EA200701648A1 (ru) | 2008-02-28 |
| FR2881426A1 (fr) | 2006-08-04 |
| MA29264B1 (fr) | 2008-02-01 |
| UY29361A1 (es) | 2006-08-31 |
| JP2008528661A (ja) | 2008-07-31 |
| KR20070103420A (ko) | 2007-10-23 |
| EP1856043B1 (de) | 2011-06-08 |
| ZA200706338B (en) | 2008-11-26 |
| FR2881426B1 (fr) | 2007-03-30 |
| NO20074414L (no) | 2007-11-05 |
| US7560571B2 (en) | 2009-07-14 |
| EP1856043A1 (de) | 2007-11-21 |
| TW200640857A (en) | 2006-12-01 |
| WO2006082309A1 (fr) | 2006-08-10 |
| EA012267B1 (ru) | 2009-08-28 |
| CA2595987A1 (fr) | 2006-08-10 |
| BRPI0606761A2 (pt) | 2009-07-14 |
| US20080045542A1 (en) | 2008-02-21 |
| AU2006210343A1 (en) | 2006-08-10 |
| CN101133023A (zh) | 2008-02-27 |
| MX2007009442A (es) | 2008-03-10 |
| IL184710A0 (en) | 2007-12-03 |
| AR053540A1 (es) | 2007-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE512133T1 (de) | 1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs | |
| ATE527241T1 (de) | Pyridiazinonderivate zur behandlung von tumoren | |
| DE602006006354D1 (de) | Pinolensäure zur Behandlung von Übergewicht | |
| ATE447570T1 (de) | Pyrimidinderivate zur verwendung als vanilloidrezeptorliganden und deren verwendung bei der behandlung von schmerzen | |
| DE602008002843D1 (de) | Neue antimikrobielle verbindungen, ihre synthese und ihre verwendung zur behandlung von säugetierinfektionen | |
| ATE447559T1 (de) | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen | |
| ATE451363T1 (de) | 3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs | |
| DE602005017503D1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
| ATE521365T1 (de) | Kinin-antagonisten zur behandlung von blasenfunktionsstörung | |
| ATE481984T1 (de) | Vakzine-peptid-kombinationen gegen katzenallergie | |
| DE602006017367D1 (de) | Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut | |
| ATE532507T1 (de) | Neramexane zur behandlung von subakuten tinnitus | |
| DE602007011398D1 (de) | Trialkylsilylbenzylaminocarboxyindole, indazole und indoline und ihre verwendung zur behandlung von cetp-vermittelten erkrankungen | |
| ATE428712T1 (de) | 4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren | |
| DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
| DE602006007323D1 (de) | VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN | |
| ATE504297T1 (de) | Visnadin zur behandlung von kopfhautjucken | |
| DE602005019341D1 (de) | System zur Behandlung von Sterilisationskassetten mit visuellem Dual-Kode Leser | |
| DE602004021435D1 (de) | Injizierbare zusammensetzung zur behandlung von krebs | |
| DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen | |
| DE602006013009D1 (de) | Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs | |
| DE602006007976D1 (de) | Benzimidazolderivate und deren verwendung zur modulation des gabaa-rezeptorkomplexes | |
| DE602006007542D1 (de) | Einheit zur sterilisierung und depyrogenierung von containern | |
| DE602005019770D1 (de) | Medizinische zusammensetzung zur behandlung von krebs oder diabetes | |
| ATE503481T1 (de) | Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von rückenmarksverletzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |